Anti-inflammatory and anti-thrombotic properties of AChE-Inhibitor treatment in Alzheimer’s patients

• Conditions: G30; Alzheimer disease

• Registration Number: DRKS00011641
• Lead Sponsor: Institut für Transfusionsmedizin und Immunologie Abteilung Molekularbiologie, UMM, Medizinische Fakultät Mannheim, Universität Heidelberg

Brief Summary

AD patients showed significantly lower aggregation response to ADP and arachidonic acid and significantly decreased CD62P and CD63 surface expression induced by ADP and U46619 compared to HC. Relative nAChRa7 and CAV-1 expression was significantly higher AD platelets than in HC. Multivariate analysis of 63 parameter revealed significant differences between AD patients and healthy controls. The best performing feature model revealed a sensitivity of 96.6%, a specificity of 80.0%, and a positive predictive value of 89.3%. No grouping could be achieved by using single parameter groups. Conclusion: Significant differences between platelet characteristics from AD patients and HC at the time of first clinical diagnosis were observed. The best performing parameter can be used as a blood-based biomarker for AD diagnosis in a multivariate model in addition to the standardized mental tests.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-02-24
• Study Completion: 2017-12-31
• Results First Posted: 2019-03-20
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 83

Inclusion Criteria

physically healthy patients with Alzheimer's disease (guidelines-based diagnoses), able to give consent form, as well as mentally healthy controls (specialist examination).

Exclusion Criteria

coagulation deficits

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Function of nACh-receptors on thrombocytes will be examined by laboratory messures at timepoints T0= before tretment with AchE-I, T1=after 4 weeks treatment with Rivastigmine 4,6 mg/24 hrs transdermal, after 4 weeks treatment with Rivastigmine 9,5 mg/24 hrs transdermal, after 12 weeks treatment with Rivastigmine 9,5 mg/24 hrs transdermal<br><br>

Secondary Outcome Measures

Name	Time	Method
coagulation parameters will be examined by laboratory messures at timepoints T0= before tretment with AchE-I, T1=after 4 weeks treatment with Rivastigmine 4,6 mg/24 hrs transdermal, after 4 weeks treatment with Rivastigmine 9,5 mg/24 hrs transdermal, after 12 weeks treatment with Rivastigmine 9,5 mg/24 hrs transdermal<br><br>